Head-To-Head Survey: CardioGenics (OTCMKTS:CGNH) versus Inogen (NASDAQ:INGN)

Inogen (NASDAQ:INGN) and CardioGenics (OTCMKTS:CGNH) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Valuation & Earnings

This table compares Inogen and CardioGenics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67 million	0.48	-$22.75 million	($0.86)	-7.09
CardioGenics	N/A	N/A	N/A	N/A	N/A

CardioGenics has lower revenue, but higher earnings than Inogen.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Inogen and CardioGenics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1	1	1	0	2.00
CardioGenics	0	0	0	0	0.00

Inogen presently has a consensus target price of $11.00, indicating a potential upside of 80.30%. Given Inogen’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Inogen is more favorable than CardioGenics.

Risk and Volatility

Inogen has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, CardioGenics has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500.

Profitability

This table compares Inogen and CardioGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inogen	-6.52%	-11.56%	-7.42%
CardioGenics	N/A	N/A	N/A

Insider & Institutional Ownership

89.9% of Inogen shares are held by institutional investors. 1.5% of Inogen shares are held by company insiders. Comparatively, 41.4% of CardioGenics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.